Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Transfus Med ; 25(2): 106-10, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25870030

RESUMEN

BACKGROUND: In Pakistan routine blood group typing of thalassemia patients identifies ABO and Rh(D) antigens only. Therefore, other antigen incompatibilities between blood donor and blood recipient may cause alloimmunisation. OBJECTIVE: The aim of this study was to estimate the frequency of alloimmunisation and to evaluate the risk factors associated with its development in beta (ß)-thalassemia patients receiving regular blood transfusions. MATERIALS AND METHODS: In total 162 ß thalassemia patients were included in this study. An extended red cell antigen panel was performed to detect antibodies. Patients received red cell concentrates, which were matched for ABO and Rh(D) antigens. Clinical and laboratory data were collected and analysed to estimate the frequency of alloantibodies and the factors influencing immunisation in patients on regular blood transfusion. RESULTS: The median age of patients was 6·7 (range: 0·5-25) years. A total of 14 (8·6%) patients developed alloantibodies against red cell antigens. The most frequently occurring alloantibodies was anti-E (2·5%), anti-K (1·8%), anti-e (1·2%) and anti-D (0·6%). Five (3·1%) patients developed more than one red blood cell (RBC) alloantibody. Age at first transfusion in alloimmunised patients was 1·22 ± 0·87 years. The frequency of blood transfusion in alloimmunised patients was 23 ± 8·81 days and in those without alloimmunisation was 31·8 ± 16 days (p = 0·02). Logistic regression analysis showed no independent risk factor associated with alloimmunisation. CONCLUSION: The frequency of transfusion was increased in patients who developed alloantibodies. Typing patients and donors to match for Rh and Kell antigens would prevent more than 90% of RBC alloantibodies and reduce the frequency of transfusion in thalassemia patients.


Asunto(s)
Incompatibilidad de Grupos Sanguíneos/epidemiología , Eritrocitos/inmunología , Reacción a la Transfusión , Talasemia beta/terapia , Adolescente , Antígenos de Grupos Sanguíneos/inmunología , Incompatibilidad de Grupos Sanguíneos/etiología , Tipificación y Pruebas Cruzadas Sanguíneas/métodos , Niño , Preescolar , Estudios Transversales , Humanos , Lactante , Isoanticuerpos/sangre , Sistema del Grupo Sanguíneo de Kell/inmunología , Pakistán , Sistema del Grupo Sanguíneo Rh-Hr/inmunología , Esplenectomía , Adulto Joven , Talasemia beta/inmunología , Talasemia beta/cirugía
2.
Hematol Oncol Clin North Am ; 14(1): 89-112, ix, 2000 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-10680074

RESUMEN

This article reviews the current state of knowledge regarding cancer screening in the geriatric population. Care of the elderly requires knowledge of underlying physiologic changes, comorbidities, quality-of-life factors, and life expectancies. There is always the danger that ageism may prevent elderly cancer patients from receiving the proper treatment. On the other hand, overzealous treatment can lead to adverse results if elderly patients are not properly targeted based on current evidence of the benefits and risks of specific screening practices.


Asunto(s)
Tamizaje Masivo , Neoplasias/diagnóstico , Factores de Edad , Anciano , Anciano de 80 o más Años , Costos y Análisis de Costo , Femenino , Humanos , Masculino , Neoplasias/economía , Neoplasias/fisiopatología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA